Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» AbbVie Is Set to Lose on Its Biggest Blockbuster. Here's Why You Shouldn't Worry.
AbbVie Is Set to Lose on Its Biggest Blockbuster. Here's Why You Shouldn't Worry.
AbbVie Is Set to Lose on Its Biggest Blockbuster. Here's Why You Shouldn't Worry.
Submitted by
admin
on January 22, 2023 - 1:01pm
Source:
Motley Fool
News Tags:
AbbVie
Humira
biosimilars
Headline:
AbbVie Is Set to Lose on Its Biggest Blockbuster. Here's Why You Shouldn't Worry.
snippet:
AbbVie’s top-selling drug, Humira, is set to face competition this year.
The blockbuster’s sales topped $20 billion in 2021.
But AbbVie has a plan to keep the company's sales growing -- even if Humira sales decline significantly.
Do Not Allow Advertisers to Use My Personal information
